MariMed Inc. (MRMD)
OTCQX OTCQX Primary 
CNSX 
Here's Why MariMed Inc. (MRMD) Could be Great Choice for a Bottom Fisher
MariMed Inc. (MRMD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
MariMed Inc. (MRMD) Q1 2026 Earnings Call Transcript
MariMed Inc. (MRMD) Q1 2026 Earnings Call Transcript
MariMed Inc. (MRMD) Reports Q1 Loss, Beats Revenue Estimates
MariMed Inc. (MRMD) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.01 per share a year ago.
MariMed Inc. (MRMD) Q4 2025 Earnings Call Transcript
MariMed Inc. (MRMD) Q4 2025 Earnings Call Transcript
MariMed Inc. (MRMD) Reports Q3 Loss, Misses Revenue Estimates
MariMed Inc. (MRMD) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to break-even earnings per share a year ago.
Despite Fast-paced Momentum, MariMed Inc. (MRMD) Is Still a Bargain Stock
MariMed Inc. (MRMD) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
MariMed Inc. (MRMD) Q2 2025 Earnings Call Transcript
MariMed Inc. (OTCQX:MRMD) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Jake Dean - Director of Research and Development Jon R. Levine - Co-Founder, CEO, President, Secretary, Treasurer & Director Mario Pinho - Chief Financial Officer Ryan Crandall - Chief Commercial Officer Conference Call Participants Andrew Semple - Ventum Financial Corp., Research Division Joseph Anthony Gomes - NOBLE Capital Markets, Inc., Research Division Pablo Ernesto Zuanic - Zuanic & Associates Operator Good morning.
MariMed Inc. (MRMD) Reports Break-Even Earnings for Q2
MariMed Inc. (MRMD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to break-even earnings per share a year ago.
MariMed Inc. (MRMD) Q1 2025 Earnings Call Transcript
MariMed Inc. (OTCQX:MRMD) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Kevin Compagna - Head of Wholesale, Sales Jon Levine - Chief Executive Officer Ryan Crandall - Chief Commercial Officer Mario Pinho - Chief Financial Officer Conference Call Participants Andrew Semple - Ventum Financial Pablo Zuanic - Zuanic & Associates Joe Gomes - Noble Capital Operator Good morning. My name is Constantine, and I will be your conference operator today.
MariMed Inc. (MRMD) Reports Q1 Loss, Lags Revenue Estimates
MariMed Inc. (MRMD) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to break-even earnings per share a year ago.
MariMed Inc. (MRMD) Q4 2024 Earnings Call Transcript
MariMed Inc. (OTCQX:MRMD) Q4 2024 - Earnings Conference Call March 6, 2025 8:00 AM ET Company Participants Sara Rosenfield - Brand Manager Jon Levine - CEO Ryan Crandall - Chief Revenue Officer Mario Pinho - CFO Conference Call Participants Andrew Semple - Ventum Financial Pablo Zuanic - Zuanic and Associates Joe Gomes - Noble Capital Operator Good morning. My name is Angeline, and I will be your conference operator today.
Is MariMed A Safe Haven In The Wake Of Florida's Cannabis Legalization Defeat?
Cannabis company MariMed Inc. MRMD released its Q3 2024 results on November 6, announcing revised guidance for the fiscal year. While the company expects an 18–20% decline in EBITDA – down from its prior projection of flat to 2% growth – it raised its sales guidance to a 6–8% increase, up from 5–7%.
